# Study of Weight-Reducing Effect and Safety of Rimonabant In Obesity in ASIA (RIO-ASIA)

> **NCT00325546** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 643 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Rimonabant (SR141716)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00325546
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2007-04
- **Final completion:** 2007-04
- **Target enrollment:** 643 (ACTUAL)
- **Last updated:** 2009-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00325546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00325546, "Study of Weight-Reducing Effect and Safety of Rimonabant In Obesity in ASIA (RIO-ASIA)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00325546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*